secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-07-29T11:31:02+00:00
Accession:  0001140361-26-029960
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q2 2026 revenue $268M, operating loss $102M; eplontersen misses ATTR-CM endpoint
--------------------------------------------------------------------------------

- Total revenue $268M (down 41% YoY); excluding one-time sapablursen payment, revenue up 56% YoY.
- Operating loss from operations $102M vs income $140M in Q2 2025; non-GAAP operating loss $57M.
- TRYNGOLZA net sales $5M in Q2, $32M in H1; DAWNZERA net sales $26M in Q2, $42M in H1.
- Eplontersen CARDIO-TTRansform missed primary composite endpoint in overall population; nominal significance in monotherapy.
- Zilganersen NDA under FDA Priority Review with PDUFA Sept 22, 2026; on track for launch this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/0001140361-26-029960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer